drugset
drugset / Trial / NCT07210515

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

NCT07210515 ↗

Phase 3 Recruiting 270 enrolled Ambros Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Phase 3 Trial of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1

Timeline

Start
2026-04-14
Primary completion
2027-12
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Neridronate Unknown 100 mg Intravenous

Indications

complex regional pain syndrome type 1